Cargando…

Vonoprazan Fumarate for the Treatment of Gastric Ulcers: A Short Review on Emerging Data

Potassium-competitive acid blockers (P-CABs), such as vonoprazan, represent a novel and heterogeneous class of drugs that competitively block the potassium binding site of gastric H(+)/K(+) ATPase, thus potentially overcoming the limitations of proton-pump inhibitors. Different studies evaluated the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marabotto, Elisa, Ziola, Sebastiano, Savarino, Vincenzo, Giannini, Edoardo Giovanni, Furnari, Manuele, Bodini, Giorgia, Zingone, Fabiana, Ghisa, Matteo, Barberio, Brigida, Zentilin, Patrizia, Savarino, Edoardo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7169470/ https://www.ncbi.nlm.nih.gov/pubmed/32346304 http://dx.doi.org/10.2147/CEG.S228352

Ejemplares similares

Not All Patients With Non-erosive Reflux Disease Share Psychological Distress as Main Mechanism of Disease
por: Savarino, Edoardo, et al.
Publicado: (2014)

The Lyon Consensus: Does It Differ From the Previous Ones?
por: Ghisa, Matteo, et al.
Publicado: (2020)

Prevalence of Lactose Intolerance in Patients with Hashimoto Thyroiditis and Impact on LT4 Replacement Dose
por: Marabotto, Elisa, et al.
Publicado: (2022)

Prevention Strategies for Esophageal Cancer—An Expert Review
por: Marabotto, Elisa, et al.
Publicado: (2021)

Pathophysiological Studies Are Mandatory to Understand the Benefit of Proton Pump Inhibitors in Patients with Idiopathic Pulmonary Fibrosis
por: Savarino, Edoardo, et al.
Publicado: (2016)

Relevance of Measuring Substances in Bronchoalveolar Lavage Fluid for Detecting Aspiration-associated Extraesophageal Reflux Disease
por: Savarino, Edoardo, et al.
Publicado: (2017)

Nuts and Non-Alcoholic Fatty Liver Disease: Are Nuts Safe for Patients with Fatty Liver Disease?
por: Plaz Torres, Maria Corina, et al.
Publicado: (2020)

Impedance-detected Symptom Association and Number of Reflux Episodes as Pre-treatment Parameters That Predict Outcomes of Gastroesophageal Reflux Disease Patients
por: Savarino, Edoardo, et al.
Publicado: (2015)

Reorganization of the functional gastrointestinal disorders unit during the SARS-CoV-2 outbreak - Practical Recommendations
por: Ghisa, Matteo, et al.
Publicado: (2020)

Optimal management of constipation associated with irritable bowel syndrome
por: Furnari, Manuele, et al.
Publicado: (2015)

Clopidogrel-Induced Eosinophilic Colitis
por: Djahandideh Sheijani, Shirin, et al.
Publicado: (2023)

Infliximab Originator, Infliximab Biosimilar, and Adalimumab Are More Effective in Crohn's Disease Than Ulcerative Colitis: A Real-Life Cohort Study
por: Barberio, Brigida, et al.
Publicado: (2020)

Lack of complications in patients with eosinophilic gastrointestinal diseases during SARS-CoV-2 outbreak
por: Savarino, Edoardo, et al.
Publicado: (2020)

Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?
por: Plaz Torres, Maria Corina, et al.
Publicado: (2020)

Colorectal Cancer in Inflammatory Bowel Diseases: Epidemiology and Prevention: A Review
por: Marabotto, Elisa, et al.
Publicado: (2022)

Pharmacological Management of Gastro-Esophageal Reflux Disease: An Update of the State-of-the-Art
por: Savarino, Vincenzo, et al.
Publicado: (2021)

Clinical and Psychological Impact of COVID-19 Infection in Adult Patients with Eosinophilic Gastrointestinal Disorders during the SARS-CoV-2 Outbreak
por: Savarino, Edoardo Vincenzo, et al.
Publicado: (2020)

The Adherence to Infusible Biologic Therapies in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic: Is It Really a Problem?
por: Barberio, Brigida, et al.
Publicado: (2021)

Drugs for improving esophageal mucosa defense: where are we now and where are we going?
por: Savarino, Edoardo, et al.
Publicado: (2017)

Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation
por: Barberio, Brigida, et al.
Publicado: (2022)

Dietary Management of Eosinophilic Esophagitis: Tailoring the Approach
por: Visaggi, Pierfrancesco, et al.
Publicado: (2021)

Good efficacy and safety of vedolizumab in Crohn’s disease and ulcerative colitis in a real-world scenario
por: Zingone, Fabiana, et al.
Publicado: (2020)

Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak
por: Zingone, Fabiana, et al.
Publicado: (2020)

Azathioprine monotherapy withdrawal in inflammatory bowel diseases: A retrospective mono-centric study
por: Crepaldi, Martina, et al.
Publicado: (2023)

Rapid point-of-care anti-infliximab antibodies detection in clinical practice: comparison with ELISA and potential for improving therapeutic drug monitoring in IBD patients
por: Facchin, Sonia, et al.
Publicado: (2021)

Medical and gastroenterological education during the COVID-19 outbreak
por: Barberio, Brigida, et al.
Publicado: (2020)

Esophageal dysmotility in patients with eosinophilic esophagitis: pathogenesis, assessment tools, manometric characteristics, and clinical implications
por: Visaggi, Pierfrancesco, et al.
Publicado: (2022)

Efficacy and safety of oral beclomethasone dipropionate and budesonide MMX versus 5-aminosalicylates or placebo in ulcerative colitis: a systematic review and meta-analysis
por: Barberio, Brigida, et al.
Publicado: (2023)

Faecal microbiota transplantation in Clostridioides difficile infection: real-life experience from an academic Italian hospital
por: Barberio, Brigida, et al.
Publicado: (2020)

Mediterranean Diet and NAFLD: What We Know and Questions That Still Need to Be Answered
por: Plaz Torres, Maria Corina, et al.
Publicado: (2019)

Quality-of-Life Evaluation in Coeliac Patients on a Gluten-Free Diet
por: Marsilio, Ilaria, et al.
Publicado: (2020)

Idiopathic pulmonary fibrosis and GERD: links and risks
por: Ghisa, Matteo, et al.
Publicado: (2019)

Screening for active COVID-19 infection and immunization status prior to biologic therapy in IBD patients at the time of the pandemic outbreak
por: Zingone, Fabiana, et al.
Publicado: (2020)

Modern Diagnosis of Early Esophageal Cancer: From Blood Biomarkers to Advanced Endoscopy and Artificial Intelligence
por: Visaggi, Pierfrancesco, et al.
Publicado: (2021)

A specific microbiota signature is associated to various degrees of ulcerative colitis as assessed by a machine learning approach
por: Barberio, Brigida, et al.
Publicado: (2022)

Novel impedance‐pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastro‐oesophageal reflux disease according to Lyon Consensus
por: Ribolsi, Mentore, et al.
Publicado: (2021)

Should Patients With Inflammatory Bowel Disease Be Tested for Active COVID-19 Before Starting a Biological Treatment?
por: Barberio, Brigida, et al.
Publicado: (2021)

A More In-depth Evaluation of Impedance-pH Could Assist in Distinguishing Reflux-related From Reflux-unrelated Heartburn
por: de Bortoli, Nicola, et al.
Publicado: (2015)

Reply to comment: Asymptomatic screening for SARS COV-2 prior to commencement of biologic therapies in patients with inflammatory bowel disease - a potentially harmful practice
por: Zingone, Fabiana, et al.
Publicado: (2020)

Reply to comment: Screening for active COVID-19 infection prior to biologic therapy in IBD patients: primum non nŏcēre
por: Zingone, Fabiana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dp1daj2pupbcb2fngsicfk77ai